Program
Multivalent Group B streptococcus vaccine
Also written as “Multivalent group B streptococcus vaccine”.
Its studies are mostly in Streptococcal Infections, led by Pfizer.
Furthest: phase 3, since Aug 14, 20254 company-led studies, 1 open or runningNext primary completion: Nov 6, 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 41 open or running | phase 3since Aug 14, 2025 | May 26, 2017 | Nov 6, 2028phase 3 · NCT07160244 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 26, 2017First study: phase 2 study in Streptococcal InfectionsFirst studyNCT03170609 · 365 enrolled · United States
- Dec 4, 2018Phase 2 study in Group B Streptococcus InfectionsNCT03765073 · 1,208 enrolled · United States, South Africa, United Kingdom
- Feb 18, 2021Phase 2 study in Group B Streptococcus InfectionsNCT04766086 · 306 enrolled · United States
- Aug 14, 2025Phase 3 study in HealthyNCT07160244 · 6,000 planned · United States, Argentina, Brazil and more
Ahead
- Nov 6, 2028Primary completion: phase 3 study in HealthyNCT07160244
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Multivalent Group B streptococcus vaccine”name, by rule
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07160244Healthy · United States, Argentina, Brazil and more | 3 | Recruiting | Nov 6, 2028 | 6,000 |
| NCT04766086Group B Streptococcus Infections · United States | 2 | Completed | Apr 27, 2023 | 306 |
| NCT03765073Group B Streptococcus Infections · United States, South Africa, United Kingdom | 2 | Completed | Mar 4, 2024 | 1,208 |
| NCT03170609Streptococcal Infections · United States | 2 | Completed | Jun 25, 2018 | 365 |
How it is read
Names in the registry
- “Multivalent Group B streptococcus vaccine”, 3 entries
- “Multivalent group B streptococcus vaccine”, 1 entry
Conditions, from the studies’ own filings
- Streptococcal Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.